A Feasibility Study to Assess a Window of Opportunity Strategy for Targeted PARP or MEK Inhibition in Patients with Pancreatic Ductal Adenocarcinoma
The purpose of this study is to understand the biology of your pancreatic cancer.
Pancreatic Ductal Adenocarcinoma, Olaparib, Cobimetinib
- Age ≥ 18 years or < 78 years
- Biopsy proven adenocarcinoma of the pancreas
- No history of previous chemotherapy
- No recent major surgery within 4 weeks prior to starting study treatment. Minor surgery within 2 weeks of starting study treatment. Must be recovered from effects of surgery.
18 - 78
Healthy Volunteers Needed
Duration of Participation
Approximately 70 days
Knight Clinical Trials Information Line